![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 36 36" xmlns="http://www.w3.org/2000/svg"><path d="M 19 18 L 36 18 L 36 19 L 19 19 L 19 36 L 18 36 L 18 19 L 0 19 L 0 18 L 18 18 L 18 0 L 19 0 Z" fill="rgb(255, 255, 255)" height="36px" id="zGS8DWzeh" width="36px"/></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 36 36" xmlns="http://www.w3.org/2000/svg"><path d="M 19 18 L 36 18 L 36 19 L 19 19 L 19 36 L 18 36 L 18 19 L 0 19 L 0 18 L 18 18 L 18 0 L 19 0 Z" fill="rgb(255, 255, 255)" height="36px" id="SCKJPsPDW" width="36px"/></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 575 575" xmlns="http://www.w3.org/2000/svg"><path d="M 287.5 575 C 446.282 575 575 446.282 575 287.5 C 575 128.718 446.282 0 287.5 0 C 128.718 0 0 128.718 0 287.5" fill="transparent" height="575px" id="XINTwJ_kr" stroke-dasharray="2,6" stroke-linecap="round" stroke-linejoin="round" stroke-width="1" stroke="rgb(255, 255, 255)" width="575px"/></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 437 437" xmlns="http://www.w3.org/2000/svg"><path d="M 437 218.5 C 437 97.826 339.174 0 218.5 0 C 97.826 0 0 97.826 0 218.5 C 0 339.174 97.826 437 218.5 437" fill="transparent" height="437px" id="x4TBJrhbE" stroke-dasharray="2,6" stroke-linecap="round" stroke-linejoin="round" stroke-width="1" stroke="rgb(255, 255, 255)" width="437px"/></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 353 705" xmlns="http://www.w3.org/2000/svg"><path d="M 0 705 C 194.68 705 352.5 547.18 352.5 352.5 C 352.5 157.82 194.68 0 0 0" fill="transparent" height="705px" id="i3oYFU0c2" stroke-dasharray="2,6" stroke-linecap="round" stroke-linejoin="round" stroke-width="1" stroke="rgb(255, 255, 255)" width="352.5px"/></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 2884 1" xmlns="http://www.w3.org/2000/svg"><path d="M 1442 0 L 0 0" fill="rgb(255, 255, 255)" height="1px" id="Sh6EUmXq2" stroke-dasharray="2,6" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="1" stroke="rgb(255, 255, 255)" transform="translate(0 0.5)" width="1442px"/><path d="M 1442 0 L 0 0" fill="rgb(255, 255, 255)" height="1px" id="uUTlaGEFM" stroke-dasharray="2,6" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="1" stroke="rgb(255, 255, 255)" transform="translate(1440 0.5)" width="1442px"/></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 1 900" xmlns="http://www.w3.org/2000/svg"><path d="M 0 0 L 0 900" fill="transparent" height="900px" id="n9VS7prGc" stroke-dasharray="2,6" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="1" stroke="rgb(255, 255, 255)" transform="translate(0.5 0)" width="1px"/></svg>)
Microdosed tirzepatide provides dual GIP/GLP-1 pathway coverage at maintenance-level doses determined by your clinician. It's designed to help maintain the metabolic improvements achieved during a full-dose protocol, or to support people who want dual-pathway coverage without a full titration.
Physician monitored
Low-dose, Physician guided
Ongoing maintenance
Physician guided subcutaneous injection
Medication, clinician, follow-ups
What you
can expect
TWO PATHWAYS. MAINTENANCE DOSE. THE RESULT YOU BUILT, HELD
GUIDED LOWER-DOSE
PROTOCOL
Your clinician calibrates your dose around your goals and how you respond at lower levels. The lowest effective dose is the point. Adjustments come from how you're actually tolerating.
DUAL PATHWAY
AT MAINTENANCE
Dual GLP-1 and GIP activation at a lower dose. Two hormonal pathways still engaged, just at lower intensity. Designed for broader metabolic coverage at a gentler dose.
DESIGNED FOR
TOLERABILITY
At maintenance-level doses, side effects are generally reported as less frequent. GIP activation is associated with antiemetic properties. May mean fewer GI symptoms than full-dose GLP-1-only approaches.
ONE SIZE FITS NONE
Personalized protocols, tuned to your body.
Dr. Jonathann Kuo, MD
A dual-pathway maintenance protocol is a different conversation than a titration. For the right patient, it's the tool that keeps the result holding.
MY STORY
Oliver Woloshin, 47
I had a great experience with Enhanced Games from start to finish. The onboarding process was smooth and straightforward, and I was able to get my first order quickly without any issues.
YOU WANT THE STRONGEST DATA IN THE CATEGORY. WITH A CLINICIAN IN THE LOOP.
Tirzepatide is a clinician-prescribed dual incretin receptor agonist designed to support appetite regulation and metabolic function via GLP-1 and GIP activity. Your protocol is titrated and adjusted to your response. Individual results vary.
*Available by prescription only, if medically appropriate.
